The number of medical devices gaining approval in the US in July 2022 saw a 10% increase when compared with June 2022, according to GlobalData’s marketed products database.

The US medical devices market was worth $169.99bn in 2021 and is expected to reach $169.71bn by 2023, according to GlobalData’s analysis.

Hospital Supplies led newly approved devices in July 2022

Looking at the device sectors, Hospital Supplies held the largest share of 18% in gaining US approval during July 2022, followed by Dental Devices with 9% and Healthcare IT with 9%.

As for the US medical devices market value, the Hospital Supplies market held a 14% share worth $23.00bn in 2021 and is expected to reach $22.97bn by 2023.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData

510(k) approved medical devices dominate the US market

In July 2022, the number of new medical devices entering the US market saw a 10% increase when compared with June 2022.

GlobalData’s database indicated that 510(k) approved medical devices entering the US market, accounted for 91% of new medical devices in July 2022, compared with 95% in the previous month.

CLIA inclined by 250% in July 2022, as against 1% in June 2022. CLIA have become more common during the COVID-19 pandemic, as a speedy mechanism to bring therapeutic devices to market more quickly than the usual device approval process.

Class II devices dominated the US marketing activity for new medical devices in July 2022

During July 2022, Class II medical devices entering the market accounted for 89% of new medical devices approved in July 2022, compared with 90% in June 2022. Class I devices decreased from 8% of new device approvals in June 2022 to 6% in July 2022.

Hospital Supplies constituted the largest group of Class II devices, accounting for 15% of devices. Cardiovascular Devices topped Class III approvals at 29%. Class III devices are devices that generally pose the most risk to patients and includes implantable devices. Class I devices are of a lesser risk.

 

Company-developed devices lead US regulatory approvals during July 2022

Looking at the share of activity among medical device organisations, GlobalData’s database indicated that company-developed devices accounted for a 99% share of newly approved devices in the US during July 2022, while institute-developed marketed products held the remaining share.

In comparison, June 2022 saw a split of 99% in newly approved devices originating from private and public companies and 1% from institutes.

Methodology
The medical devices approval data used in this article were extracted from Medical Marketed Products Database of GlobalData’s Medical Intelligence Center. Marketed Products database covers all commercialized medical devices which are intended for diagnosis, treatment, and management of diseases/conditions/symptoms directly or indirectly. Marketed products are covered from regulatory bodies like US FDA, company websites, news releases, SEC filings etc. The information is collected by following systematic research techniques and proprietary methodology.